ONCO — Onconetix, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1782107 ·
Last close
$1.03
Market Cap
$4.51M
52W High
$209.50
52W Low
$0.59
ADV30
3,302,317
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 17,120 | 4,303 | -2,244,790 | -2,867,303 | 16,426,341 | 5,942,249 | 2,956,108 |
| Mar 2026 | 21,457 | -1,655 | -2,091,801 | -4,214,875 | 14,832,086 | 3,716,072 | 3,083,885 |
| Dec 2025 | 303,596 | 247,684 | -1,281,367 | 5,669,687 | 24,926,638 | 5,220,654 | 9,160,287 |
| Sep 2025 | 303,651 | 268,894 | -2,069,242 | -8,783,702 | 19,678,868 | 836,556 | 16,303,023 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,800,191
Investing CF
$0
Financing CF
$12,214,220
CapEx
$-3,874
Dividends Paid
—
Buybacks
$-395,933
EPS Diluted TTM
$-2890.10
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-135,429,433
Inventory
$137,642
Receivables
$100,063
ST Investments
—
EBIT TTM
$-9,171,150
Pretax Income TTM
$-9,700,807
Interest Exp TTM
$529,657
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$645,824
EBITDA
$-7,672,447
Free Cash Flow
$-5,920,061
Enterprise Value
$-2,768,016
Total Cash
$5,942,249
Total Debt
$187,128
Shares Out
4,380,522
Trailing EPS
$749.08
Book Value
$3.55
ROE
-105.2%
ROA
-27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 815,371 | -6,344,856 | -14,032,342 | 24,926,638 | 9,160,287 | 15,766,351 | -9,678,390 |
| Dec 2024 | 2,524,116 | -10,331,243 | -58,691,023 | 28,181,563 | 18,571,008 | 9,610,555 | -10,495,816 |
| Dec 2023 | 58,465 | -17,847,249 | -37,409,694 | 87,518,032 | 86,113,556 | -5,602,028 | -13,581,018 |
| Dec 2022 | 0 | -13,481,240 | -13,419,830 | 26,310,447 | 3,922,445 | 22,388,002 | -8,675,534 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRI | GRI Bio, Inc. | $4.48M | $2.05 | — |
| ADXN | Addex Therapeutics Ltd. | $4.62M | $3.65 | — |
| CANF | Can-Fite BioPharma Ltd. | $4.63M | $2.16 | — |
| EMMA | Emmaus Life Sciences, Inc. | $4.76M | $0.07 | — |
| PMHS | Polomar Health Services, Inc. | $4.82M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
2026-09-24 16:30 · Yahoo
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
2026-09-14 12:30 · Yahoo
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
2026-09-03 12:30 · Yahoo
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
2026-08-06 12:30 · Yahoo
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
2026-07-07 13:00 · Yahoo
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
2026-06-24 12:30 · Yahoo
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
2026-05-19 12:00 · Yahoo
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
2026-05-13 13:25 · Yahoo
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
2026-04-02 12:30 · Yahoo
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
2026-03-31 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.